Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction

Acta Cardiologica

Volumn 60, Issue 4, 2005, Pages 373-377

  Dayi, Sennur Unal ^a,c   Akbulut, Tamer ^a   Akgoz, Haldun ^a   Terzi, Sait ^a   Sayar, Nurten ^a   Aydin, Alper ^a   Bilsel, Tuba ^a   Ciloglu, Figen ^b  

^a Department of Cardiology   (Turkey)

^b GenLab Genetic Medical Laboratories Istanbul   (Turkey)

^c Nisantasi Cad Gunal Billur Sitesi   (Turkey)

Author keywords

Cardiopulmonary exercise test; Heart failure; Losartan

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ADULT; AGED; ANAEROBIC THRESHOLD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXERCISE TEST; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; LONG TERM CARE; LUNG MINUTE VOLUME; MALE; OXYGEN CONSUMPTION;

EID: 23644458575     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.60.4.2004985     Document Type: Article

References (24)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
2. The CONSENSUS Trial study group: Effects of enalapril on mortality in severe congestive heart failure. New Engl J Med 1987; 316: 1429-35.
3. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. The effects of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction: Results of the Survival and Ventricular Enlargement (SAVE) trial. New Engl J Med 1992; 327: 669-77.
5. McMurray J, Ostergren J, Swedberg K, Granger CB, Held P, Mic EL, Olofsson B, Yusuf S, Pfeffer M; CHARM investigators and C. Effects of candesartan in patients with chronic heart failure reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
6. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 155-60.
7. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J 2003; 349: 1893-1906.
8. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-7.
9. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90.
10. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997; 273: 769-74.
11. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-6.
12. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-9.
13. Birkenhager WH, deLeeuw PW. Non-peptide angiotensin type I receptor antagonists in the treatment of hypertension. J Hypertens 1999; 17: 873-8.
14. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995; 91: 691-7.
15. Wasserman K, Hansen EJ, Sue YD, Whipp JB, Casaburi R. Principles of exercise testing and interpretation. In Wasserman K, ed. Philadelphia, 1994: 53-111.
16. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53-7.
17. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15: 276-82.
18. Gadsboll N, Damkjaer Nielsen M, Giese J, Leth A, Lonborg-Jensen H. Diurnal monitoring of blood pressure and the renin-angiotensin system in hypertensive patients on long-term angiotensin converting enzyme inhibition. J Hypertens 1990; 8: 733-40.
19. Van den Meiracker AH, Man in't Veld AJ, Admiraal PJJ, Ritsema Van Eck HJ, Boomsma F, Derkx FHM, Schalekamp MA. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992; 10: 803-12.
20. The RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril and their combination in congestive heart failure. Circulation 1999; 100: 1056-64.
21. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2.
22. Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ. A study of the efficacy and safety of irbesartan in combination with convential therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract 2000; 54: 11-8.
23. Houghton AR, Harrison M, Cowley AJ, Hamptom JR. Combined treatment with losartan and ACE inhibitor in mild to moderate heart failure: results of a double-blind, randomized, placebo-controlled trial. Am Heart J 2000; 140: 791-6.
24. Fleg JL, Pina IL, Balady GJ, Chaitman BR, Fletcher B, Lavie C, Limacher MC, Stein RA, Williams M, Bazzarre T. Assessment of functional capacity in clinical and research applications. An advisory from the committee on exercise, rehabilitation and prevention, council on clinical cardiology, American Heart Association. Circulation 2000; 102: 1591-7.